Current prophylactic and therapeutic uses of a recombinant Lactococcus lactis strain secreting biologically active interleukin-12

Journal of Molecular Microbiology and Biotechnology

Volumn 14, Issue 1-3, 2008, Pages 80-89

  Bermúdez Humarán, Luis G ^a   Cortes Perez, Naima G ^a,c   Ah Leung, Sandrine ^c   Lefèvre, François ^b   Yang, Guang ^d   Pang, Qingfeng ^d   Wu, Changyi ^e   Zeng, Yinming ^e   Adel Patient, Karine ^c   Langella, Philippe ^a  

^a CEMAGREF   (France)

^b INRA Institut National de la Recherche Agronomique   (France)

^c CEA SACLAY   (France)

^d CHINA MEDICAL UNIVERSITY   (China)

^e XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Allergy; Asthma; Human papillomavirus type 16; Interleukin 12; Lactococcus lactis; Vaccines

Indexed keywords

CYTOKINE; INTERLEUKIN 12; LL E7; UNCLASSIFIED DRUG; VACCINE; VACCINE ANTIGEN;

ALLERGY; ARTICLE; ASTHMA; BACTERIAL STRAIN; CANCER; CANCER IMMUNOTHERAPY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; LACTOCOCCUS LACTIS; NONHUMAN; VACCINATION;

HUMAN PAPILLOMAVIRUS TYPE 16; LACTOCOCCUS; LACTOCOCCUS LACTIS; POSIBACTERIA;

EID: 35648935384     PISSN: 14641801     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106086     Document Type: Article

References (76)

1. Adel-Patient, K., Ah-Leung, S., Creminon, C., Nouaille, S., Chatel, J.M., Langella, P., Wal, J.M. 2005. Oral administration of recombinant Lactococcus lactis expressing bovine β-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 35:539-546.
2. Adel-Patient, K., Nahori, M.A., Proust, B., Lapa e Silva, J.R., Creminon, C., Wal, J.M., Vargaftig, B.B. 2003. Elicitation of the allergic reaction in β-lactoglobulin-sensitized Balb/c mice: biochemical and clinical manifestations differ according to the structure of the allergen used for challenge. Clin Exp Allergy 33:376-385.
3. Adel-Patient, K., Creminon, C., Bernard, H., Clement, G., Negroni, L., Frobert, Y., Grassi, J., Wal, J.M., Chatel, J.M. 2000. Evaluation of a high IgE-responder mouse model of allergy to bovine β-lactoglobulin (BLG): development of sandwich immunoassays for total and allergen-specific IgE, IgG1 and IgG2a in BLG-sensitized mice. J Immunol Methods 235:21-32.
4. Arulanandam, B.P., O'Toole, M., Metzger, D.W. 1999. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 180:940-949.
5. Arulanandam, B.P., Metzger, D.W. 1999. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine 17:252-260.
6. Bermúdez-Humarán, L.G., Cortes-Perez, N.G., Lefevre, F., Guimaraes, V., Rabot, S., Alcocer-Gonzalez, J.M., Gratadoux, J.J., Rodriguez-Padilla, C., Tamez-Guerra, R.S., Corthier, G., Gruss, A., Langella, P. 2005. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175:7297-7302.
7. Bermúdez-Humarán, L.G., Cortes-Perez, N.G., Le Loir, Y., Alcocer-Gonzalez, J.M., Tamez-Guerra, R.S., de Oca-Luna, R.M., Langella, P. 2004. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 53:427-433.
8. Bermúdez-Humarán, L.G., Langella, P., Cortes-Perez, N.G., Gruss, A., Tamez-Guerra, R.S., Oliveira, S.C., Saucedo-Cardenas, O., Montes de Oca-Luna, R., Le Loir, Y. 2003. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 71:1887-1896.
9. Bermúdez-Humarán, L.G., Langella, P., Miyoshi, A., Gruss, A., Taméz-Reyes, R. S., Montes de Oca-Luna, R., Le Loir, Y. 2002. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 68:917-922.
10. Berzofsky, J.A., Ahlers, J.D., Belyakov, I.M. 2001. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209-219.
11. Berzofsky, J.A., Ahlers, J.D., Janik, J., Morris, J., Oh, S., Terabe, M., Belyakov, I.M. 2004. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114:450-462.
12. Bjermer, L., Diamant, Z. 2004. Current and emerging non-steroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. Treat Respir Med 3:235-46.
13. Brahmbhatt, H.N., Lindberg, A.A., Timmis, K.N. 1992. Shigella lipopolysaccharide: structure, genetics, and vaccine development. Curr Top Microbiol Immunol 180:45-64.
14. Bolotin, A., Wincker, P., Mauger, S., Jaillon, O., Malarme, K., Weissenbach, J., Ehrlich, S.D., Sorokin, A. 2001. The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res 11:731-753.
15. Buchanan, J.M., Vogel, L.A., Van Cleave, V.H., Metzger, D.W. 1995. Interleukin 12 alters the isotype-restricted antibody response of mice to hen egg white lysozyme. Int Immunol 7:1519-1528.
16. Chatel, J.M., Nouaille, S., Adel-Patient, K., Le Loir, Y., Boe, H., Gruss, A., Wal, J.M., Langella, P. 2003. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine β-lactoglobulin and evaluation of its immunogenicity in mice. Appl Environ Microbiol 69:6620-6627.
17. Chatel, J.M., Langella, P., Adel-Patient, K., Commissaire, J., Wal, J.M., Corthier, G. 2001. Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine β-lactoglobulin. Clin Diagn Lab Immunol 8:545-551.
18. Cohen, J. 1995. IL-12 deaths:explanation and a puzzle. Science 270:908.
19. Cortes-Perez, N.G., Bermúdez-Humarán, L.G., Le Loir, Y., Rodriguez-Padilla, C., Gruss, A., Saucedo-Cardenas, O., Langella, P., Montesde-Oca-Luna, R. 2003. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 229:37-42.
20. Curtiss, R. 3rd., Kelly, S.M., Tinge, S.A., Tacket, C.O., Levine, M.M., Srinivasan, J., Koopman, M. 1994. Recombinant Salmonella vectors in vaccine development. Dev Biol Stand 82:23-33.
21. Drouault, S., Corthier, G., Ehrlich, S.D., Renault, P. 1999. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65:4881-4886.
22. Enouf, V., Langella, P., Commissaire, J., Cohen, J., Corthier, G. 2001. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 67:1423-1428.
23. Eriksson, K., Holmgren, J. 2002. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14:666-672.
24. Germann, T., Bongartz, M., Dlugonska, H., Hess, H., Schmitt, E., Kolbe, L., Kölsch, E., Podlaski, F.J., Gately, M.K., Rüde, E. 1995. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complementfixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 25:823-829.
25. Grangette, C., Muller-Alouf, H., Hols, P., Goudercourt, D., Delcour, J., Turneer, M., Mercenier, A. 2004. Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria. Infect Immun 72:2731-2737.
26. Grangette, C., Muller-Alouf, H., Geoffroy, M., Goudercourt, D., Turneer, M., Mercenier, A. 2002. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 20:3304-3309.
27. Grangette, C., Muller-Alouf, H., Goudercourt, D., Geoffroy, M.C., Turneer, M., Mercenier, A. 2001. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 69:1547-1553.
28. Hanniffy, S., Wiedermann, U., Repa, A., Mercenier, A., Daniel, C., Fioramonti, J., Tlaskolova, H., Kozakova, H., Israelsen, H., Madsen, S., Vrang, A., Hols, P., Delcour, J., Bron, P., Kleerebezem, M., Wells, J. 2004. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 56:1-64.
29. Huber, V.C., Arulanandam, B.P., Arnaboldi, P.M., Elmore, M.K., Sheehan, C.E., Kallakury, B.V., Metzger, D.W. 2003. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 3:801-809.
30. Iwamoto, I., Nakajima, H., Endo, H., Yoshida, S. 1993. Interferon-γ regulates antigen-induced eosinophil recruitment into the mouse airway by inhibiting the infiltration of CD4+ T cells. J Exp Med 177:573-576.
31. Jensen, E.R., Shen, H., Wettstein, F.O, Ahmed, R., Miller, J.F. 1997. Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell-mediated immunity. Immunol Rev 158:147-157.
32. Karin, N. 2004. Induction of protective therapy for autoimmune diseases by targeted DNA vaccines encoding pro-inflammatory cytokines and chemokines. Curr Opin Mol Ther 6:27-33.
33. Killeen, K., Spriggs, D., Mekalanos, J. 1999. Bacterial mucosal vaccines:Vibrio cholerae as a live attenuated vaccine/vector paradigm. Curr Top Microbiol Immunol 236:237-254.
34. Lack, G., Bradley, K.L., Hamelmann, E., Renz, H., Loader, J., Leung, D.Y., Larsen, G., Gelfand, E.W. 1996. Nebulized IFN-γ inhibits the development of secondary allergic responses in mice. J Immunol 157:1432-1439.
35. Langrish, C.L., McKenzie, B.S., Wilson, N.J., de Waal Malefyt, R., Kastelein, R.A., Cua, D.J. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202:96-105.
36. Larche, M., Wraith, D.C. 2005. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11:S69-S76.
37. Lee, S.F. 2003. Oral colonization and immune responses to Streptococcus gordonii: potential use as a vector to induce antibodies against respiratory pathogens. Curr Opin Infect Dis 16:231-235.
38. Leonard, J.P., Sherman, M.L., Fisher, G.L., Buchanan, L.J., Larsen, G., Atkins, M.B., Sosman, J.A., Dutcher, J.P., Vogelzang, N.J., Ryan, J.L. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90:2541-2548.
39. Levine, M.M. 2003. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9:99-103.
40. Locht, C. 2000. Live bacterial vectors for intranasal delivery of protective antigens. Pharm Sci Technol Today 3:121-128.
41. Lotze, M.T., Zitvogel, L., Campbell, R., Robbins, P.D., Elder, E., Haluszczak, C., et al. 1996. Cytokine gene therapy of cancer using interleukin-12:murine and clinical trials. Ann NY Acad Sci 795:440-454.
42. Maassen, C.B., Laman, J.D., den Bak-Glashouwer, M.J., Tielen, F.J., van Holten-Neelen, J. C., Hoogteijling, L., Antonissen, C., Leer R.J., Pouwels, P.H., Boersma, W.J., Shaw, D. M. 1999. Instruments for oral disease-intervention strategies:recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine 17:2117-2128.
43. Madaan, A., Maddox, D.E. 2003. Vaccine allergy: diagnosis and management. Immunol Allergy Clin North Am 23:555-588.
44. Makela, P.H. 2000. Vaccines, coming of age after 200 years. FEMS Microbiol Rev 24:9-20.
45. Medina, E., Guzman, C.A. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19:1573-1580.
46. Mielcarek, N., Alonso, S., Locht, C. 2001. Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev 51:55-69.
47. Moneret-Vautrin, D.A., Morisset, M., Flabbee, J., Beaudouin, E., Kanny, G. 2005. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 60:443-451.
48. Mosmann, T.R., Coffman, R.L. 1989. Th1 and Th2 cells:different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173.
49. Motzer, R.J., Rakhit, A., Schwartz, L.H., Olencki, T., Malone, T.M., Sandstrom, K., et al. 1998. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4:1183-1191.
50. Neutra, M.R, Kozlowski, P.A. 2006. Mucosal vaccines:the promise and the challenge. Nat Rev Immunol 6:148-158.
51. Neutra, M.R., Frey, A., Kraehenbuhl, J.P. 1996. Epithelial M cells:gateways for mucosal infection and immunization. Cell 86:345-348.
52. Noben-Trauth, N., Schweitzer, P.A., Johnson, K.R., Wolf, S.F., Knowles, B.B., Shultz, L.D. 1996. The interleukin-12 β subunit (p40) maps to mouse chromosome 11. Mammal Genome 7:392-393.
53. Norton, P.M., Brown, H.W., Le Page, R.W. 1994. The immune response to Lactococcus lactis: implications for its use as a vaccine delivery vehicle. FEMS Microbiol Lett 120:249-256.
54. Norton, P.M., Wells, J.M., Brown, H.W., Macpherson, A.M., Le Page, R.W. 1997. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 15:616-619.
55. Nouaille, S., Bermúdez-Humarán, L.G., Adel-Patient, K., Commissaire, J., Gruss, A., Wal, J.M., Azevedo, V., Langella, P., Chatel, J.M. 2005. Improvement of bovine β-lactoglobulin production and secretion by Lactococcus lactis. Braz J Med Biol Res 38:353-359.
56. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275-283.
57. Ouwehand, A.C., Salminen, S., Isolauri, E. 2002. Probiotics:an overview of beneficial effects. Antonie Van Leeuwenhoek 82:279-289.
58. Paludan, S.R. 1998. Interleukin-4 and interferon-γ: the quintessence of a mutual antagonistic relationship. Scand J Immunol 48:459-468.
59. Parkin, D.M., Pisani, P., Ferlay, J. 1999. Global cancer statistics. CA Cancer J Clin 49:33-64.
60. Pontes, D.S., Dorella, F.A., Ribeiro, L.A., Miyoshi, A., Le Loir, Y., Gruss, A., Oliveira, S.C., Langella, P., Azevedo, V. 2003. Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J Drug Target 11:489-493.
61. Rautava, S., Kalliomaki, M., Isolauri, E. 2005. New therapeutic strategy for combating the increasing burden of allergic disease:probiotics - a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol 116:31-37.
62. Robinson, K., Chamberlain, L.M., Lopez, M.C., Rush, C.M., Marcotte, H., Le Page, R.W., Wells, J.M. 2004. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect Immun 72:2753-27561.
63. Robinson, K., Chamberlain, L.M., Schofield, K.M., Wells, J.M., Le Page, R.W. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 15:653-657.
64. Romagnani, S. 2004. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 112:352-363.
65. Rosenberg, S.A., Yang, J.C., Restifo, N.P. 2004. Cancer immunotherapy:moving beyond current vaccines. Nat Med 10:909-915.
66. Sabin, A.B. 1960. Oral, live poliovirus vaccine for elimination of poliomyelitis. Arch Intern Med 106:5-9.
67. Salminen, S., von Wright, A., Morelli, L., Marteau, P., Brassart, D., de Vos, W.M., Fonden, R., Saxelin, M., Collins, K., Mogensen, G., Birkeland, S.E., Mattila-Sandholm, T. 1998. Demonstration of safety of probiotics a review. Int J Food Microbiol 44:93-106.
68. Sampson, H.A. 2004. Update on food allergy. J Allergy Clin Immunol 113:805-819.
69. Schweitzer, P.A., Noben-Trauth, N., Pelsue, S.C., Johnson, K.R., Wolf, S.F., Shultz, L.D. 1996. Genetic mapping of the IL-12 α chain gene (IL12α) on mouse chromosome 3. Mammal Genome 7:394-395.
70. Seegers, J.F. 2002 Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 20:508-515.
71. Ståhl, S., Samuelson, P., Hansson., M., Andréoni, C., Goetsch, L., Libon, C., Liljeqvist, S., Gunneriusson., E., Binz, H., Nguyen, T.N., Uhlén, M. 1997. Development of non-pathogenic staphylococci as vaccine delivery vehicles; in Wells, J., Pozzi, G. (eds). Recombinant Gram-Positive Bacteria as Vaccine Vehicles for Mucosal Immunization. New York, Landes Biomedical Publishers/Springer, pp 61-81.
72. Steidler, L., Robinson, K., Chamberlain, L., Schofield, M., Remaut, E., Le Page, R.W.F. Wells, J.M. 1998. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 66:3183-3189.
73. Stevenson, A., Roberts, M. 2003. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol Med Microbiol 37:121-128.
74. Stover, C.K., de la Cruz, V.F., Bansal, G.P., Hanson, M.S., Fuerst, T.R., Jacobs, W.R. Jr., Bloom, B.R. 1992. Use of recombinant BCG as a vaccine delivery vehicle. Adv Exp Med Biol 327:175-182.
75. von Mutius, E. 2004. Influences in allergy: epidemiology and the environment. J Allergy Clin Immunol 113:373-379.
76. Wu, C., Yang, G., Bermúdez-Humarán, L.G., Qingfeng, P., Yinming, Z., Wang, J., Gao, X. 2006. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. Int Immunopharmacol 6:610-615.